# Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure

> **NCT00391287** · — · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 15334 (actual)

## Conditions studied

- Pure Red-Cell Aplasia
- Chronic Kidney Failure

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00391287
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 15334 (ACTUAL)
- **Last updated:** 2014-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391287, "Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00391287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*